Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12.

Morillon YM 2nd, Su Z, Schlom J, Greiner JW.

J Immunother Cancer. 2019 Jun 11;7(1):150. doi: 10.1186/s40425-019-0620-2.

2.

Immunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder Cancer.

Ingersoll MA, Li X, Inman BA, Greiner JW, Black PC, Adam RM.

Bladder Cancer. 2018 Oct 29;4(4):429-440. doi: 10.3233/BLC-180175.

3.

Enhanced immunotherapy by combining a vaccine with a novel murine GITR ligand fusion protein.

Morillon YM 2nd, Hammond SA, Durham NM, Schlom J, Greiner JW.

Oncotarget. 2017 Sep 7;8(43):73469-73482. doi: 10.18632/oncotarget.20703. eCollection 2017 Sep 26.

4.

Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody.

Fallon JK, Vandeveer AJ, Schlom J, Greiner JW.

Oncotarget. 2017 Mar 28;8(13):20558-20571. doi: 10.18632/oncotarget.16137.

5.

An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele.

Jochems C, Hodge JW, Fantini M, Fujii R, Morillon YM 2nd, Greiner JW, Padget MR, Tritsch SR, Tsang KY, Campbell KS, Klingemann H, Boissel L, Rabizadeh S, Soon-Shiong P, Schlom J.

Oncotarget. 2016 Dec 27;7(52):86359-86373. doi: 10.18632/oncotarget.13411.

6.

Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.

Vandeveer AJ, Fallon JK, Tighe R, Sabzevari H, Schlom J, Greiner JW.

Cancer Immunol Res. 2016 May;4(5):452-62. doi: 10.1158/2326-6066.CIR-15-0176. Epub 2016 Feb 26.

7.

Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis.

Tucker JA, Jochems C, Boyerinas B, Fallon J, Greiner JW, Palena C, Rodell TC, Schlom J, Tsang KY.

Cancer Immunol Immunother. 2014 Dec;63(12):1307-17. doi: 10.1007/s00262-014-1603-2. Epub 2014 Sep 4.

8.

Therapeutic cancer vaccines.

Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, Farsaci B, Madan RA, Heery CR, Gulley JL.

Adv Cancer Res. 2014;121:67-124. doi: 10.1016/B978-0-12-800249-0.00002-0. Review.

9.

The immunocytokine NHS-IL12 as a potential cancer therapeutic.

Fallon J, Tighe R, Kradjian G, Guzman W, Bernhardt A, Neuteboom B, Lan Y, Sabzevari H, Schlom J, Greiner JW.

Oncotarget. 2014 Apr 15;5(7):1869-84.

10.

Inhibition of TGF-β1 signaling promotes central memory T cell differentiation.

Takai S, Schlom J, Tucker J, Tsang KY, Greiner JW.

J Immunol. 2013 Sep 1;191(5):2299-307. doi: 10.4049/jimmunol.1300472. Epub 2013 Jul 31.

11.

Distinct effects of saracatinib on memory CD8+ T cell differentiation.

Takai S, Sabzevari H, Farsaci B, Schlom J, Greiner JW.

J Immunol. 2012 May 1;188(9):4323-33. doi: 10.4049/jimmunol.1101439. Epub 2012 Mar 26.

12.

Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies.

Bonmassar L, Fossile E, Scoppola A, Graziani G, Prete SP, Formica V, Cappelletti D, De Vecchis L, Cardillo A, Concolino F, D'Atri S, Balduzzi A, Torino F, Caporaso P, Greiner JW, Bonmassar E, Roselli M, Aquino A.

Anticancer Res. 2010 Nov;30(11):4721-30.

PMID:
21115931
13.

In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines.

Heffernan MJ, Zaharoff DA, Fallon JK, Schlom J, Greiner JW.

Biomaterials. 2011 Jan;32(3):926-32. doi: 10.1016/j.biomaterials.2010.09.058. Epub 2010 Oct 20.

14.

Intratumoral immunotherapy of established solid tumors with chitosan/IL-12.

Zaharoff DA, Hance KW, Rogers CJ, Schlom J, Greiner JW.

J Immunother. 2010 Sep;33(7):697-705. doi: 10.1097/CJI.0b013e3181eb826d.

15.

Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12.

Zaharoff DA, Hoffman BS, Hooper HB, Benjamin CJ Jr, Khurana KK, Hance KW, Rogers CJ, Pinto PA, Schlom J, Greiner JW.

Cancer Res. 2009 Aug 1;69(15):6192-9. doi: 10.1158/0008-5472.CAN-09-1114. Epub 2009 Jul 28.

16.

The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines.

Hance KW, Rogers CJ, Zaharoff DA, Canter D, Schlom J, Greiner JW.

Clin Cancer Res. 2009 Apr 1;15(7):2387-96. doi: 10.1158/1078-0432.CCR-08-1752. Epub 2009 Mar 10.

17.

Exercise enhances vaccine-induced antigen-specific T cell responses.

Rogers CJ, Zaharoff DA, Hance KW, Perkins SN, Hursting SD, Schlom J, Greiner JW.

Vaccine. 2008 Oct 3;26(42):5407-15. doi: 10.1016/j.vaccine.2008.07.081. Epub 2008 Aug 14.

18.

Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses.

Wansley EK, Chakraborty M, Hance KW, Bernstein MB, Boehm AL, Guo Z, Quick D, Franzusoff A, Greiner JW, Schlom J, Hodge JW.

Clin Cancer Res. 2008 Jul 1;14(13):4316-25. doi: 10.1158/1078-0432.CCR-08-0393.

19.

Physical activity and cancer prevention : pathways and targets for intervention.

Rogers CJ, Colbert LH, Greiner JW, Perkins SN, Hursting SD.

Sports Med. 2008;38(4):271-96. Review.

PMID:
18348589
20.

Targeted delivery of murine IFN-gamma using a recombinant fowlpox virus: NK cell recruitment to regional lymph nodes and priming of tumor-specific host immunity.

Zeytin H, Reali E, Zaharoff DA, Rogers CJ, Schlom J, Greiner JW.

J Interferon Cytokine Res. 2008 Feb;28(2):73-87. doi: 10.1089/jir.2007.0063.

21.

Energy restriction and exercise differentially enhance components of systemic and mucosal immunity in mice.

Rogers CJ, Berrigan D, Zaharoff DA, Hance KW, Patel AC, Perkins SN, Schlom J, Greiner JW, Hursting SD.

J Nutr. 2008 Jan;138(1):115-22.

22.

Chitosan solution enhances the immunoadjuvant properties of GM-CSF.

Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW.

Vaccine. 2007 Dec 17;25(52):8673-86. Epub 2007 Nov 5.

23.

Combination of physical activity, nutrition, or other metabolic factors and vaccine response.

Hance KW, Rogers CJ, Hursting SD, Greiner JW.

Front Biosci. 2007 Sep 1;12:4997-5029. Review.

24.

Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination.

Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW.

Vaccine. 2007 Mar 1;25(11):2085-94. Epub 2006 Dec 4.

25.

TRICOM vector based cancer vaccines.

Garnett CT, Greiner JW, Tsang KY, Kudo-Saito C, Grosenbach DW, Chakraborty M, Gulley JL, Arlen PM, Schlom J, Hodge JW.

Curr Pharm Des. 2006;12(3):351-61. Review.

PMID:
16454749
26.

Costimulatory molecules as adjuvants for immunotherapy.

Hodge JW, Greiner JW, Tsang KY, Sabzevari H, Kudo-Saito C, Grosenbach DW, Gulley JL, Arlen PM, Marshall JL, Panicali D, Schlom J.

Front Biosci. 2006 Jan 1;11:788-803. Review.

PMID:
16146771
27.
28.

Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms.

Reali E, Canter D, Zeytin H, Schlom J, Greiner JW.

Vaccine. 2005 Apr 22;23(22):2909-21.

PMID:
15780740
29.

Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation.

Schlom J, Palena C, Greiner JW, Tsang KY, Grosenbach DW, Sabzevari H, Gulley JL, Arlen PM, Kass E, Hodge JW.

Dev Biol (Basel). 2004;116:27-47. No abstract available.

PMID:
15603182
30.

Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice.

Zeytin HE, Patel AC, Rogers CJ, Canter D, Hursting SD, Schlom J, Greiner JW.

Cancer Res. 2004 May 15;64(10):3668-78.

31.

Enhanced expression of lymphotactin by CD8+ T cells is selectively induced by enhancer agonist peptides of tumor-associated antigens.

Palena C, Arlen P, Zeytin H, Greiner JW, Schlom J, Tsang KY.

Cytokine. 2003 Nov 21;24(4):128-42.

PMID:
14572791
33.

Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice.

Schmitz J, Reali E, Hodge JW, Patel A, Davis G, Schlom J, Greiner JW.

Cancer Res. 2002 Sep 1;62(17):5058-64.

34.

Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer.

Kass ES, Greiner JW, Kantor JA, Tsang KY, Guadagni F, Chen Z, Clark B, De Pascalis R, Schlom J, Van Waes C.

Cancer Res. 2002 Sep 1;62(17):5049-57.

35.

Pharmacological modulation of carcinoembryonic antigen in human cancer cells: studies with staurosporine.

Prete SP, Cappelletti D, Baier S, Nasuti P, Guadagni F, De Vecchis L, Greiner JW, Bonmassar E, Graziani G, Aquino A.

Int Immunopharmacol. 2002 Apr;2(5):641-51.

PMID:
12013504
36.

IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines.

Reali E, Greiner JW, Corti A, Gould HJ, Bottazzoli F, Paganelli G, Schlom J, Siccardi AG.

Cancer Res. 2001 Jul 15;61(14):5517-22.

37.

Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.

Guadagni F, Kantor J, Aloe S, Carone MD, Spila A, D'Alessandro R, Abbolito MR, Cosimelli M, Graziano F, Carboni F, Carlini S, Perri P, Sciarretta F, Greiner JW, Kashmiri SV, Steinberg SM, Roselli M, Schlom J.

Cancer Res. 2001 Mar 15;61(6):2523-32.

38.

Drug-induced modulation of carcinoembryonic antigen (CEA) expression in neoplastic cells from a patient with rectal cancer.

Cappelletti D, Cardillo A, Bonanno E, Prete SP, Cucchiara G, Turriziani M, Greiner JW, Cottarelli A, Breda E, Aquino A, Bonmassar E, De Vecchis L.

J Exp Clin Cancer Res. 2000 Dec;19(4):467-9.

PMID:
11277324
40.

Effect of 5-fluorouracil on carcinoembryonic antigen expression and shedding at clonal level in colon cancer cells.

Aquino A, Prete SP, Guadagni F, Greiner JW, Giuliani A, Orlando L, Masci G, De Santis S, Bonmassar E, Graziani G.

Anticancer Res. 2000 Sep- Oct;20(5B):3475-84.

PMID:
11131650
42.

Staurosporine increases carcinoembryonic antigen expression in a human colon cancer cell line.

Aquino A, Prete SP, Baier S, Cappelletti D, Greiner JW, De Vecchis L, Graziani G, Bonmassar E.

J Chemother. 2000 Apr;12(2):167-72.

PMID:
10789557
43.
44.
45.

Novel clinical approaches in monoclonal antibody-based management in colorectal cancer patients: radioimmunoguided surgery and antigen augmentation.

Roselli M, Buonomo O, Piazza A, Guadagni F, Vecchione A, Brunetti E, Cipriani C, Amadei G, Nieroda C, Greiner JW, Casciani CU.

Semin Surg Oncol. 1998 Dec;15(4):254-62. Review.

PMID:
9829383
46.

Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.

Macey DJ, Grant EJ, Kasi L, Rosenblum MG, Zhang HZ, Katz RL, Rieger PT, LeBherz D, South M, Greiner JW, Schlom J, Podoloff DA, Murray JL.

Clin Cancer Res. 1997 Sep;3(9):1547-55.

47.

Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells.

Aquino A, Prete SP, Greiner JW, Giuliani A, Graziani G, Turriziani M, De Filippi R, Masci G, Bonmassar E, De Vecchis L.

Clin Cancer Res. 1998 Oct;4(10):2473-81.

48.
49.

Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: lack of correlation.

Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Arcuri R, D'Alessandro R, Fracasso PL, Casale V, Vecchione A, Casciani CU, Greiner JW, Schlom J.

Int J Cancer. 1997 Sep 17;72(6):949-54.

50.

Dacarbazine-induced immunogenicity of a murine leukemia is attenuated in cells transfected with mutated K-ras gene.

Testorelli C, Bussini S, De Filippi R, Marelli O, Orlando L, Greiner JW, Grohmann U, Tentori L, Giuliani A, Bonmassar E, Graziani G.

J Exp Clin Cancer Res. 1997 Mar;16(1):15-22.

PMID:
9148855

Supplemental Content

Loading ...
Support Center